1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
Perspective
You have free access to this content
Atrial fibrillation and bisphosphonate therapy
Article first published online: 20 JAN 2010
DOI: 10.1359/jbmr.091201
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Pazianas, M., Compston, J. and Huang, C. L.-H. (2010), Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res, 25: 2–10. doi: 10.1359/jbmr.091201
Publication History
- Issue published online: 20 JAN 2010
- Article first published online: 20 JAN 2010
- Manuscript Accepted: 1 DEC 2010
- Manuscript Revised: 20 NOV 2009
- Manuscript Received: 19 JUL 2009
References
- 1, , , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370–2375.
- 2, . Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008; 5: 30–41.
- 3, , , et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27: 949–953.
- 4, . Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92: 17–40.
- 5Drug Topics. Top 200 brand-name drugs by units in 2006. Available at: www.drugtopics.com/drugtopics/Pharmacy+Facts+And+Figures/Top-200-brand-name-drugs-by-units-in-2006/ArticleStandard/Article/detail/407649?contextCategoryId=7604. Accessed December 9, 2008.
- 6, , , et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
- 7PhVWP assessment report on bisphosphonates and atrial fibrillation. September 2008. Available at: http://docs.google.com/gview?a=v&attid=0.1&thid=1208109362726c8b&mt=application%2Fpdf&pli=1.
- 8, , . Alendronate and atrial fibrillation. N Engl J Med. 2007; 356: 1895–1896.
- 9, , , et al. for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809.
- 10, , . Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357: 712–713.
- 11, , , et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 336: 813–816.
- 12, , . Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009; 265: 581–592.Direct Link:
- 13, , , , . Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008; 168: 826–831.
- 14Food and Drug Administration (FDA). The FDA safety information and adverse event reporting program. Available at: www.fda.gov/medwatch/safety/2008/safety08.htm#bisphosphonates2. Accessed November 15, 2008.
- 15, , , , . Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE. 2009; 4: e4720.
- 16, , , et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003; 98: 1735–1744.Direct Link:
- 17, , . Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32: 219–228.
- 18, , , , . Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized, controlled trials and observational studies. BMC Musculoskel Disord. 2009; 10: 113.
- 19, , , , , . Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912–1920.Direct Link:
- 20, , , , . Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008; 5: 782–796.
- 21, , , et al. Crosstalk between L-type calcium channels and ZnT-1, a new player in rate-dependent cardiac electrical remodeling. Cell Calcium. 2008; 42: 71–82.
- 22, . Calcium-mediated triggered activity is an underlying cellular mechanism of ectopy originating from the pulmonary vein in dogs. Am J Physiol Heart Circ Physiol. 2007; 292: H1861–1867.
- 23, , , et al. Pharmacological alterations of cellular Ca2+ homeostasis parallel initiation of atrial arrhythmogenesis in Langendorff perfused murine hearts. Clin Exp Pharmacol Physiol. 2009; 36: 969–980.Direct Link:
- 24, , , et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004; 110: 1358–1363.
- 25, . Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol. 2008; 52: 293–299.
- 26, . Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol. 2000; 32: 1101–1117.
- 27. Magnesium depletion and hypermagnesemia. In: FavusMJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Chap. 40 ASBMR Washington, DC: ASBMR; 2006: 230–233.
- 28, , , , , . Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart. 2005; 91: 618–623.
- 29, , . Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007; 93: 1433–1440.
- 30, , , , , . Gap junction alterations in human cardiac disease. Cardiovasc Res. 2004; 62: 368–377.
- 31. Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Curr Opin Cardiol. 2006; 21: 155–158.
- 32, , , et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation. 2001; 103: 842–849.
- 33, , , et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001; 38: 883–891.
- 34, , , , , . Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002; 54: 361–379.
- 35, , , et al. A new role for extracellular Ca2+ in gap-junction remodeling: studies in humans and rats. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377: 125–138.
- 36, , , . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
- 37, , , et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int. 1998; 63: 230–235.
- 38, . Clodronate inhibits contraction and prevents the action of L-type calcium channel antagonists in vascular smooth muscle. J Bone Miner Res. 1991; 6: 835–841.Direct Link:
- 39, , . Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol. 1991; 68: 284–286.Direct Link:
- 40, , , et al. Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascular Pharmacol. 2009; 51: 350–358.
- 41, , , et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008; 45: 742–753.
- 42, , , et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004; 43: 818–825.
- 43, , , , , . Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003; 107: 1930–1936.
- 44, , , , , . Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008; 51: 2053–2057.
- 45, , , et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol. 2005; 36: 1080–1089.
- 46, , , et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch. 2004; 445: 498–505.
- 47, , , et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302: 1055–1061.
- 48, , , et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538–6544.
- 49, , , et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun. 2003; 310: 816–823.
- 50, , , et al. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res. 2002; 22: 3925–3931.
- 51, , , et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997; 57: 3890–3894.
- 52, , , et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci. 1998; 878: 453–465.Direct Link:
- 53, , . An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004; 114: 623–633.
- 54, , , . Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol. 2004; 93: 1176–1178.
- 55, , , et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004; 291: 1720–1729.
- 56, , , , , . Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180–1184.
- 57, , , et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108: 3006–3010.
- 58, , . Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006; 27: 136–149.
- 59, . Inflammation and atrial fibrillation: cause or effect? Heart. 2008; 94: 133–134.
- 60, , , , , . The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005; 139: 101–111.Direct Link:
- 61, , , et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J Cardiovasc Pharmacol Ther. 2009; 14: 68–75.
- 62, , , , . Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol. 2008; 19: 74–81.
- 63, , , . Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006; 69: 865–875.
- 64, . Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004; 25: 1100–1107.
- 65, , , et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth. 2007; 21: 68–75.
- 66, , , et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007; 297: 1562–1567.
- 67, , , , , . Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009; 169: 1677–1683.
- 68, , , et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 1980; 77: 3957–3961.
- 69, , , , , . Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998; 13: 581–589.Direct Link:
- 70, , , et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA. 1999; 96: 133–138.
- 71. Statins: lower lipids and better bones? Nat Med. 2000; 6: 21–23.
- 72, , . The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004; 62: 105–111.
- 73, , , . Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004; 110: 2313–2319.
- 74, . Prevention of atrial fibrillation: another good reason to recommend statins to women? Heart. 2009; 95: 693–694.
- 75, , , et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006; 97: 55–60.
- 76, , , , , . Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2008; 135: 405–411.
- 77, , , , . Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: The HERS Trial. Heart. 2009; 95: 704–708.
- 78, , , et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008; 155: 541–546.